Pharmaceutical News

RSS

Evolution of vaccine adjuvants from empirical discovery to rational design

Vaccine adjuvants have evolved significantly since their inception, transitioning from empirical discovery to a more structured approach grounded in rational drug design.

13 Sep 2024

Study sheds light on potential demand for psilocybin-assisted therapy for depression in the U.S.

In the wake of mounting evidence for the efficacy of psychedelic-assisted therapies, the U.S. Food and Drug Administration (FDA) is considering approving psilocybin, the active ingredient in "magic mushrooms," for treating depression in the near future.

13 Sep 2024

GLP-2 regulates appetite by influencing gut-brain communication and gastrointestinal motility

Researchers examine the role of GLP-2 in regulating food intake through its effects on gastrointestinal motility and satiety signals, offering insights into potential obesity treatments.

12 Sep 2024

COVID-19 vaccines prevented millions of deaths across Latin America and the Caribbean, study shows

Researchers estimate that COVID-19 vaccines averted between 610,000 and 2.62 million deaths in select Latin American and Caribbean countries from early 2021 to May 2022.

12 Sep 2024

Pharma companies' strategies for reaching poorer countries remain unclear

Pharmaceutical companies must prioritize efforts to reach patients in underserved parts of the world with medicines such as insulin for diabetics and, crucially, measure the effectiveness of these efforts, says Jayasree Iyer, CEO of the Access to Medicine Foundation.

12 Sep 2024

New IndiPHARM initiative aims to revolutionize personalized medication management

A Columbia University-led multicenter research effort called IndiPHARM: individual metabolome and exposome assessment for pharmaceutical optimization will develop a platform and monitoring system to prevent unwanted interactions between medications and other environmental, genetic, and lifestyle factors, in order to optimize therapeutic efficacy.

12 Sep 2024

Molnupiravir reduces long-term COVID-19 symptoms but shows limited impact on hospitalizations

Molnupiravir treatment for COVID-19 shows modest long-term benefits, reducing symptoms and improving well-being at three and six months. However, the differences were small, with no impact on hospitalization rates.

11 Sep 2024

Ropirio Therapeutics secures exclusive license for novel lymphatic system activators

The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard's Office of Technology Development (OTD) and Boston University (BU)'s Technology Development office for novel molecules that activate the lymphatic system - a first in the pharma industry.

11 Sep 2024

Study highlights barriers to discussing therapeutic psychedelics with physicians

Feeling safe and comfortable are key when discussing your health and wellbeing with your primary care provider.

10 Sep 2024

Statins found to be cost-effective and linked to better health outcomes in older adults

Statin treatment is cost-effective and linked to better health outcomes in older people with or without previous cardiovascular disease, although the risk reductions were substantially smaller in the latter, reports a modeling on the lifetime benefits of these drugs among the over-70s, published online in the journal Heart.

10 Sep 2024

Sulthiame shows promise in reducing obstructive sleep apnea symptoms

Patients taking sulthiame, a drug currently in use for epilepsy, experienced a reduction in their symptoms of obstructive sleep apnoea (OSA), according to results of a clinical trial presented at the European Respiratory Society (ERS) Congress in Vienna, Austria.

10 Sep 2024

GLP-1 receptor agonists show promise in treating substance use disorders

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

9 Sep 2024

Systemic glucocorticoid use doubles risk of developing diabetes

Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear.

9 Sep 2024

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year's annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

9 Sep 2024

Long COVID significantly affects children for up to 36 months, vaccines offer crucial protection

Study reveals the significant and lasting impact of long COVID on children, emphasizing the protective role of vaccines and the increased risk of autoimmune disorders.

8 Sep 2024

HKUST researchers unveil eco-friendly disinfectant alternative to chloroxylenol

A widely used disinfectant worldwide, chloroxylenol, has been associated with eco-toxicological threats in water environments due to its relatively high chemical stability and massive consumption.

6 Sep 2024

Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemic

Semaglutide significantly reduces all-cause mortality in non-diabetic obese patients, particularly by lowering infection-related deaths during the COVID-19 pandemic. However, the study's findings should be interpreted with caution due to potential competing risks and unique pandemic circumstances.

5 Sep 2024

Combined use of insulin and metformin enhances diabetic foot ulcer healing, research shows

People with chronic diabetic foot ulcers could soon have a new way to treat their wounds for faster healing and fewer hospital stays.

4 Sep 2024

Semaglutide does not increase risk of depression or suicidal thoughts

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal Medicine.

4 Sep 2024

Alirocumab reduces dangerous coronary plaque and stabilizes high-risk lesions

Intensive LDL-C lowering with alirocumab significantly reduces high-risk coronary plaque burden, transforming unstable plaques into more stable phenotypes. This lesion-level analysis underscores the enhanced efficacy compared to vessel-level approaches.

4 Sep 2024

Previous
1
...
14
15
16
17
18
19
20
...
1443
Next

Pharmaceutical News

Evolution of vaccine adjuvants from empirical discovery to rational design

Study sheds light on potential demand for psilocybin-assisted therapy for depression in the U.S.

GLP-2 regulates appetite by influencing gut-brain communication and gastrointestinal motility

COVID-19 vaccines prevented millions of deaths across Latin America and the Caribbean, study shows

Pharma companies' strategies for reaching poorer countries remain unclear

New IndiPHARM initiative aims to revolutionize personalized medication management

Molnupiravir reduces long-term COVID-19 symptoms but shows limited impact on hospitalizations

Ropirio Therapeutics secures exclusive license for novel lymphatic system activators

Study highlights barriers to discussing therapeutic psychedelics with physicians

Statins found to be cost-effective and linked to better health outcomes in older adults

Sulthiame shows promise in reducing obstructive sleep apnea symptoms

GLP-1 receptor agonists show promise in treating substance use disorders

Systemic glucocorticoid use doubles risk of developing diabetes

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

Long COVID significantly affects children for up to 36 months, vaccines offer crucial protection

HKUST researchers unveil eco-friendly disinfectant alternative to chloroxylenol

Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemic

Combined use of insulin and metformin enhances diabetic foot ulcer healing, research shows

Semaglutide does not increase risk of depression or suicidal thoughts

Alirocumab reduces dangerous coronary plaque and stabilizes high-risk lesions

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News